Integrative Statistics, Machine Learning and Artificial Intelligence Neural Network Analysis Correlated CSF1R with the Prognosis of Diffuse Large B-Cell Lymphoma

Tumor-associated macrophages (TAMs) of the immune microenvironment play an important role in the Diffuse Large B-cell Lymphoma (DLBCL) pathogenesis. This research aimed to characterize the expression of macrophage colony-stimulating factor 1 receptor (CSF1R) at the gene and protein level in correlation with survival. First, the immunohistochemical expression of CSF1R was analyzed in a series of 198 cases from Tokai University Hospital and two patterns of histological expression were found, a TAMs, and a diffuse B-lymphocytes pattern. The clinicopathological correlations showed that the CSF1R + TAMs pattern associated with a poor progression-free survival of the patients, disease progression, higher MYC proto-oncogene expression, lower MDM2 expression, BCL2 translocation, and a MYD88 L265P mutation. Conversely, a diffuse CSF1R + B-cells pattern was associated with a favorable progression-free survival. Second, the histological expression of CSF1R was also correlated with 10 CSF1R-related markers including CSF1, STAT3, NFKB1, Ki67, MYC, PD-L1, TNFAIP8, IKAROS, CD163, and CD68. CSF1R moderately correlated with STAT3, TNFAIP8, CD68, and CD163 in the cases with the CSF1R + TAMs pattern. In addition, machine learning modeling predicted the CSF1R immunohistochemical expression with high accuracy using regression, generalized linear, an artificial intelligence neural network (multilayer perceptron), and support vector machine (SVM) analyses. Finally, a multilayer perceptron analysis predicted the genes associated with the CSF1R gene expression using the GEO GSE10846 DLBCL series of the Lymphoma/Leukemia Molecular Profiling Project (LLMPP), with correlation to the whole set of 20,683 genes as well as with an immuno-oncology cancer panel of 1790 genes. In addition, CSF1R positively correlated with SIRPA and inversely with CD47. In conclusion, the CSF1R histological pattern correlated with the progression-free survival of the patients of the Tokai series, and predictive analytics is a feasible strategy in DLBCL.

[1]  Jianguo Xu,et al.  CD47: the next checkpoint target for cancer immunotherapy. , 2020, Critical reviews in oncology/hematology.

[2]  Emili Montserrat,et al.  High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.

[3]  Juan F. García,et al.  CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma , 2015, PloS one.

[4]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Wilcox A three‐signal model of T‐cell lymphoma pathogenesis , 2016, American journal of hematology.

[6]  J. Pollard,et al.  Diverse Functions of Macrophages in Different Tumor Microenvironments. , 2018, Cancer research.

[7]  Joaquim Carreras,et al.  Artificial Intelligence Analysis of the Gene Expression of Follicular Lymphoma Predicted the Overall Survival and Correlated with the Immune Microenvironment Response Signatures , 2020, Mach. Learn. Knowl. Extr..

[8]  The UniProt Consortium,et al.  UniProt: a worldwide hub of protein knowledge , 2018, Nucleic Acids Res..

[9]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[10]  K. Gu,et al.  Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count , 2019, BMC Cancer.

[11]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[12]  N. Nakamura,et al.  MYD88 (L265P) Mutation in Malignant Lymphoma Using Formalin-Fixed Paraffin-Embedded Section. , 2013, Journal of clinical and experimental hematopathology : JCEH.

[13]  W. Chan,et al.  Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[15]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. , 2010, Blood.

[16]  K. Elenitoba-Johnson,et al.  Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability , 2019, Clinical Cancer Research.

[17]  K. Ando,et al.  Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients , 2018, The American journal of surgical pathology.

[18]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[19]  Juan F. García,et al.  Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS) , 2017, Histopathology.

[20]  Jun Zhu,et al.  High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma , 2011, Journal of hematology & oncology.

[21]  R. Hamoudi,et al.  A Combination of Multilayer Perceptron, Radial Basis Function Artificial Neural Networks and Machine Learning Image Segmentation for the Dimension Reduction and the Prognosis Assessment of Diffuse Large B-Cell Lymphoma , 2021, AI.

[22]  R. Gascoyne,et al.  An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.

[23]  R. Hamoudi,et al.  Artificial Intelligence Analysis of Gene Expression Data Predicted the Prognosis of Patients with Diffuse Large B-Cell Lymphoma. , 2020, The Tokai journal of experimental and clinical medicine.

[24]  Y. Okuno,et al.  Expression of IL‐34 correlates with macrophage infiltration and prognosis of diffuse large B‐cell lymphoma , 2019, Clinical & translational immunology.

[25]  A. Lánczky,et al.  Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets , 2018, Scientific Reports.

[26]  S. McWeeney,et al.  Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples , 2018, Oncotarget.

[27]  A. Rosenwald,et al.  High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation , 2019, Journal of clinical and experimental hematopathology : JCEH.

[28]  W. Denny,et al.  Small-molecule CSF1R kinase inhibitors; review of patents 2015-present , 2020, Expert opinion on therapeutic patents.

[29]  C. Ries,et al.  Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. , 2017, Journal for immunotherapy of cancer.

[30]  R. Hamoudi,et al.  A Single Gene Expression Set Derived from Artificial Intelligence Predicted the Prognosis of Several Lymphoma Subtypes; and High Immunohistochemical Expression of TNFAIP8 Associated with Poor Prognosis in Diffuse Large B-Cell Lymphoma , 2020, Applied Informatics.

[31]  Wen-Qi Jiang,et al.  Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study , 2017, Chinese journal of cancer.

[32]  C. Lindskog,et al.  A pathology atlas of the human cancer transcriptome , 2017, Science.

[33]  James J. Driscoll,et al.  Overall Survival: Still the Gold Standard: Why Overall Survival Remains the Definitive End Point in Cancer Clinical Trials , 2009, Cancer journal.

[34]  Xiaoyun Lu,et al.  Small-Molecule CSF1R Inhibitors as Anticancer Agents. , 2019, Current medicinal chemistry.

[35]  R. Bociek,et al.  CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial , 2012 .

[36]  K. Akashi,et al.  Combination of CD47 and signal‐regulatory protein‐α constituting the “don’t eat me signal” is a prognostic factor in diffuse large B‐cell lymphoma , 2020, Cancer science.

[37]  R. Xiang,et al.  M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma , 2016, Scientific Reports.

[38]  A. López-Guillermo,et al.  High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Ohshima,et al.  Role of tumor‐associated macrophages in hematological malignancies , 2015, Pathology international.

[40]  J. Andrechak,et al.  Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function , 2020, Antibody therapeutics.

[41]  L. Staudt,et al.  High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy , 2011, Haematologica.

[42]  P. Boonstra,et al.  Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia , 2016, Clinical Cancer Research.

[43]  R. Fehrmann,et al.  CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL , 2019, Cancer Immunology Research.